Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of capecitabine + vinorelbine versus sequential single-agent use in metastatic breast cancer
2009-013472-41Phase 2Terminated
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Dec 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine and vinorelbine in breast cancer (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Second disease-progression free period. Started Dec 2009; status: terminated.
02
Drugs
capecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-013472-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013472-41.